

FORM 7

MONTHLY PROGRESS REPORT

Name of CSE Issuer: **M-Pharmaceutical Inc. ("M-Pharmaceutical")** *formerly First Sahara Energy Inc. ("First Sahara")*

Trading Symbol: MQ

Number of Outstanding Listed Securities: **142,733,434**

Date: March 5, 2015

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by the CSE Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the CSE.ca website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the CSE Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

The Issuer closed on Feb. 19, 2015 closed the acquisition of the intellectual property associated with the eMosquito device and technology by the purchase of M Diagnostics Inc., a private company. The Issuer paid US\$ 150,000 on closing and issued 8,066,670 common shares, all which are

subject to a 3 year escrow, with 10% being immediately releasable, and the balance in 6 equal installments over the next 3 years.

A royalty of 3% will accrue on the commercial sale of any related products.

The Issuer entered into an agreement to sell its remaining oil and gas and mining assets to an arms-length private company for a deemed price of \$250,000, payable by the issuance of 10,000,000 shares of the private company at a deemed price of \$0.025.

The Issuer is actively looking at other strategic medical devices to add to its portfolio so as to diversify its product mix and reduce market sector risk.

The Issuer closed the final tranche of its financing and issued an additional 10,250,000 units at \$0.02 per unit for gross proceeds of \$205,000, for final total gross proceeds of \$1,080,000. Each unit consists of one common share in the capital of the Company (a "Common Share") and one Common Share purchase warrant (a "Warrant") entitling the holder to purchase one additional Common Share for \$0.05 for a period of 12 months from closing.

2. Provide a general overview and discussion of the activities of management. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

Management focused on raising funds further to the private placement and on closing the proposed licensed bio-medical technology and closing of the above reference PP.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required un Ontario securities law.

Management focused on obtaining rights for the M Mosquito technology.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

None applicable.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

The Issuer entered into an arm's-length agreement to acquire and commercialize the rights to a biomedical device for the self-monitoring of

blood glucose, primarily by diabetics. This device, called the eMosquito, is designed to be a minimally invasive skin penetration device to be used by persons with diabetes.

The Issuer entered into an agreement to receive shares of Hills Energy Corp, in exchange for the resource assets of the Company.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

No contracts or agreements between M-Pharmaceutical Inc. and any other parties expired or were terminated during this period.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

The Issuer disposed of significantly all of its legacy natural resource properties to complete the exit from the natural resource business. The disposition included: the Rosevale oil and gas leases located in the province of New Brunswick and the La Pause mining claims located in the province of Quebec. The Company received shares of a private company with a deemed value of \$250,000. The Company had attempted to market the assets for some time and was unable to attract a cash sale. The carrying value of the resources assets was approximately \$80,000 immediately prior to the sale. The consideration was determined through a process of actively marketing the resource claims and selling to the highest bidder.

8. Describe the acquisition of new customers or loss of customers.

Not applicable.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

Not applicable.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

Not applicable.

11. Report on any labour disputes and resolutions of those disputes if applicable.

Not applicable.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

M-Pharmaceutical Inc. did not become a party to any legal proceedings during this period.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

No indebtedness occurred during this period.

14. Provide details of any securities issued and options or warrants granted.

The Issuer closed on Feb. 19, 2015 closed the acquisition of the intellectual property associated with the eMosquito device and technology where it issued 8,066,670 common shares, all which are subject to a 3 year escrow, with 10% being immediately releasable, and the balance in 6 equal installments over the next 3 years.

The Issuer closed the both tranches of its financing and issued 53,200,000 units at \$0.02 per unit for final total gross proceeds of \$1,080,000. Each unit consists of one common share in the capital of the Company (a "Common Share") and one Common Share purchase warrant (a "Warrant") entitling the holder to purchase one additional Common Share for \$0.05 for a period of 12 months from closing.

15. Provide details of any loans to or by Related Persons.

No loans were made to or by Related Persons during this period.

16. Provide details of any changes in directors, officers or committee members.

Not applicable.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

Not applicable during this period.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to CSE that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in

National Instrument 14-101) and all CSE Requirements (as defined in CSE Policy 1).

4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: March 5th, 2015

David Lane, President

//David Lane//

Signature

Director

Official Capacity

<i>Issuer Details</i> Name of Issuer M-Pharmaceutical Inc.	For Month End February, 2015	Date of Report March 5 th , 2015
Issuer Address 430-580 Hornby Street		
City/Province/Postal Code Vancouver, B.C. V6C 3B3	Issuer Fax No.	Issuer Fax No. (604) 428 0512
Contact Name David Lane	Contact Position President & CEO	Contact Telephone No. (604) 428 0511
Contact Email Address info@m-pharma.ca	Web Site Address www.m-pharma.ca	